Bellevue Group - substantial expansion of asset management activities with a distinct profile

Thursday, 27. August 2009 18:32
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




Bellevue Group has steadfastly implemented the strategic expansion of
its asset management activities announced earlier this year. As a
specialized asset management boutique focused on investing in
healthcare stocks, "new markets" and selected stock-market niches,
the company offers a clear and distinct core competency profile. Its
offering of investment products has recently been broadened with the
launch of new vehicles that also allow Bellevue Asset Management to
address new market segments. With CHF 2.6 billion in assets under
management and an expert team of 30 highly experienced analysts,
portfolio managers and product specialists, Bellevue Group ranks
among the leading cross-border providers of investment vehicles for
the healthcare sector.

Steadfast strategic expansion
Despite the financial crisis Bellevue Group has largely completed the
strategic expansion of its asset management activities through
anti-cyclical investment in personnel and infrastructure. Expansion
has been focused on actively managed equity investment vehicles for
selected sectors and regions, based on a fundamental and
research-driven stock-picking approach. Sectors such as the
healthcare, or emerging markets that are still displaying high market
inefficiencies, are particularly suited for active investment
strategies. In these cases active portfolio management can produce
tangible value added provided the requisite skills are available.
This has led to a trend toward increasing specialization in the asset
management industry. Our positioning is based on our long-standing
and strong research skills in the healthcare industry and in Swiss
equities, two areas where we occupy a prominent position as a leading
international player. We have enhanced our expertise in new markets
and in attractive growth niches for Swiss and international equity
investments, where we are likewise focusing on long-term and
structurally driven investment trends," explains André Rüegg, Head of
Sales and Marketing at Bellevue Asset Management. "As a boutique with
a disciplined strategic focus, this has been our guiding principle
for more than 16 years."

Quantitative und qualitative expansion of portfolio management
activities
Additional specialists were recruited to build upon our long-standing
and interdisciplinary healthcare competencies with approximately CHF
2.6 billion in assets under management. An experienced team was also
hired for the newly created "New Markets" investment theme. Our
portfolio management staff was thus increased by half to a total of
24 investment specialists. This successful recruitment campaign, like
our previous success in hiring experienced client advisors and
marketing and product specialists, demonstrates Bellevue Group's
appeal to talented investment professionals on the national and
international stage. Substantial investments in corporate
infrastructure and modern risk management processes were also made
during the period of expansion in the first half of the year.

Successful launch of new products
A venture capital product, a hedge fund and five specialized UCITS
III Luxembourg-based equity funds have been added to our range of
services and products. The latter are based on the new Bellevue Funds
(Lux) Sicav and have been registered for distribution in Switzerland,
Germany, Austria and Luxembourg. This new platform will allow
Bellevue Group to expand its customer base across the European
continent. Its offering of new equity funds ranges from its
long-standing group-wide investment competency (BB Selection), to New
Markets products such as
BB Silk Road Opportunities and BB African Opportunities, to European
niche strategies
(BB Entrepreneur Europe). An equity fund under Luxembourg law was
launched on March 31, 2009 to supplement the investment company BB
Biotech, the group's flagship product with a market capitalization of
CHF 1.5 billion. The range of Luxembourg products will include the
equity fund BB Medtech (Lux) by the end of September provided the
shareholders accept the proposed transformation of the listed
investment company BB Medtech AG. The subscription period for BB
Biotech Ventures III was resoundingly successful, having attracted
some USD 100 million from institutional and private investors.

The new products have got off to a good start in terms of performance
and investor acceptance. Bellevue Asset Management now offers a
comprehensive, complementary range of products consisting of:

* Investment funds for institutional and private clients;
* Investment companies;
* Selected alternative investments in the form of hedge
funds and private equity/venture vehicles;
* Specialized institutional mandates.

Platform for future growth in place
Bellevue Group has used the financial crisis to significantly
strengthen its position. It now has outstanding growth prospects,
partly contingent on the stabilization of financial markets and
restored investor trust in stock markets.


Please direct your enquiries to:

Media: Andre Rüegg (aru@bellevue.ch), Anja Stubenrauch(
as@bellevue.ch)
Telephone +41 44 267 67 00, Fax +41 44 267 77 02



The Bellevue Group is an independent Swiss financial group domiciled
in Küsnacht. The company is listed on the Swiss stock exchanges.

Bank am Bellevue is a provider of research and brokerage services in
Swiss equities and selected international stocks as well as corporate
finance services.

Bellevue Asset Management manages specialized equity investment
vehicles focused on selected sector and regional strategies and
provides selected institutional asset management services.
Newly recruited Portfolio Managers / Analysts at Bellevue Asset
Management


+-------------------------------------------------------------------+
| Last name | First name | Function | Focus | Job |
| | | | | experience |
|-----------+------------+---------------+-------------+------------|
| Bernhardt | Eric | Head | Healthcare | 24 years |
| | | Portfolio | | |
| | | Manager | | |
|-----------+------------+---------------+-------------+------------|
| Reeder | Kevin | Senior | Healthcare | 7 years |
| | | Portfolio | | |
| | | Manager | | |
|-----------+------------+---------------+-------------+------------|
| Fox | Matthew | Senior | Healthcare | 6 years |
| | | Portfolio | | |
| | | Manager | | |
|-----------+------------+---------------+-------------+------------|
| Hofmann | Corinne | Portfolio | Healthcare | 5 years |
| | | Manager | | |
|-----------+------------+---------------+-------------+------------|
| Zuzak | Miroslav | Portfolio | European | 3 years |
| | | Manager | Equities | |
| | | | | |
|-----------+------------+---------------+-------------+------------|
| Shalash | Alexander | Head | New Markets | 16 years |
| | | Portfolio | | |
| | | Manager | | |
| | | | | |
|-----------+------------+---------------+-------------+------------|
| Bou-Diab | Malek | Senior | New Markets | 6 years |
| | | Portfolio | | |
| | | Manager | | |
| | | | | |
|-----------+------------+---------------+-------------+------------|
| Ogram | Elena | Senior | New Markets | 6 years |
| | | Portfolio | | |
| | | Manager | | |
| | | | | |
+-------------------------------------------------------------------+



New equity-based fund products at Bellevue Asset Management


+---------------------------------------------------------------------------+
|Equity fund |No. of |Fees |Legal form|Investment|Currency |
| |stocks | | |style | |
| | | | | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB Biotech |30 to 40|1.60% p.a. |Luxemburg |Bottom-up |USD; (CHF,|
|(Lux) | |B-Shares |SICAV |stock |EUR |
| | |0.90% p.a. |Fonds, |picking |unhedged) |
| | |I-Shares |Partie I | | |
| | | | | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB Medtech |30 to 40|1.60% p.a. |Luxemburg |Bottom-up |EUR (CHF, |
|(Lux) | |B-Shares |SICAV |stock |unhedged) |
| | |0.90% p.a. |Fonds, |picking | |
| | |I-Shares |Partie I | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB Healthcare |30 to 50|1.60% p.a. |Luxemburg |Bottom-up |USD; (CHF,|
|(Lux)* | |B-Shares |SICAV |stock |EUR |
| | |0.90% p.a. |Fonds, |picking |unhedged) |
| | |I-Shares |Partie I | | |
| | | | | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB Selection |30 to 50|1.40% p.a. |Luxemburg |Bottom-up |EUR (CHF, |
|(Lux) | |B-Shares |SICAV |stock |unhedged) |
| | |0.80% p.a. |Fonds, |picking | |
| | |I-Shares |Partie I | | |
| | |+15% Performance | | | |
| | |Fee above 3M EUR | | | |
| | |Libor + 4% p.a. | | | |
| | | | | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB Entrepreneur|30 to 50|1.60% p.a. |Luxemburg |Bottom-up |EUR (CHF, |
|Europe (Lux) | |B-Shares |SICAV |stock |unhedged) |
| | |0.90% p.a. |Fonds, |picking | |
| | |I-Shares |Partie I | | |
| | | | | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB African |50 to 70|1.60% p.a. |Luxemburg |Bottom-up |EUR (CHF, |
|Opportunities | |B-Shares |SICAV |stock |USD, |
|(Lux) | |0.90% p.a. |Fonds, |picking |unhedged) |
| | |I-Shares |Partie I | | |
| | | | | | |
|---------------+--------+-----------------+----------+----------+----------|
|BB Silk Road |50 to 70|1.60% p.a. |Luxemburg |Bottom-up |EUR (CHF, |
|Opportunities | |B-Shares |SICAV |stock |USD, |
|(Lux) | |0.90% p.a. |Fonds, |picking |unhedged) |
| | |I-Shares |Partie I | | |
| | | | | | |
+---------------------------------------------------------------------------+

*Launch scheduled for September 30, 2009



--- End of Message ---

Bellevue Group AG
Seestrasse 16, Postfach Küsnacht/Zürich
Switzerland

WKN: A0LG3Z; ISIN: CH0028422100; Index: SPI, SPIEX, SSCI;
;

View document
Related Links: Bellevue Group AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.